Dupilumab, a fully human monoclonal antibody that has impressed equally in asthma and atopic dermatitis trials, may be approved for market as soon as March of 2017.
In the field of neurosurgery it can seem like each new day is the future. Even still there are goals to achieve that may not be reached until many years down the road.
Even though some medications for epilepsy are able to drastically reduce the number of seizures a patient suffers sometimes just one can be damaging enough to a person's quality of life.
As new medications have been approved for movement disorders like Parkinson's Disease many patients have been able to better manage their symptoms. When that is not enough newer surgical options have also been developed in recent years.
Technology may be advancing faster than people can keep up with but there are still times when traditional surgical methods are preferred over newer technologies.
While minimally invasive surgery is not a new concept the rapid advances in technology are helping to treat patients with more wide ranging conditions than ever before.
The FDA has granted approval for ustekinumab (Stelara/Janssen Biotech) to treat adults with moderately-to severely active Crohn’s disease (CD).
Panelists Peter L. Salgo, MD, and Joshua D. Lee, MD, PhD, discuss patient selection criteria for the use of long-acting naltrexone in the treatment of individuals with opioid dependency.
Peter L. Salgo, MD; Joshua D. Lee, MD, PhD; and Phillip Barbour discuss the mechanism of action for methadone and buprenorphine to prevent relapse in those who have a history of substance abuse.